Tags

Type your tag names separated by a space and hit enter

Quetiapine for agitation or psychosis in patients with dementia and parkinsonism.
Neurology. 2007 Apr 24; 68(17):1356-63.Neur

Abstract

OBJECTIVE

To assess the efficacy and tolerability of quetiapine for agitation or psychosis in patients with dementia and parkinsonism.

METHODS

Multicenter randomized, double-blind, placebo-controlled parallel groups clinical trial involving 40 patients with dementia with Lewy bodies (n = 23), Parkinson disease (PD) with dementia (n = 9), or Alzheimer disease with parkinsonian features (n = 8). The main outcome measure for efficacy was change in the Brief Psychiatric Rating Scale (BPRS) from baseline to 10 weeks of therapy. For tolerability it was change in the Unified PD Rating Scale (UPDRS) motor section over the same time period. The trial was confounded by the need for a design change and incomplete recruitment.

RESULTS

No significant differences in the primary or secondary outcome measures of efficacy were observed. An unexpectedly large placebo effect, inadequate dosage (mean 120 mg/day), and inadequate power may have contributed to lack of demonstrable benefit. Quetiapine was generally well-tolerated and did not worsen parkinsonism, but was associated with a trend toward a decline on a measure of daily functioning.

CONCLUSIONS

Quetiapine was well-tolerated and did not worsen parkinsonism. Although conclusions about efficacy may be limited, the drug in the dosages used did not show demonstrable benefit for treating agitation or psychosis in patients with dementia and parkinsonism. These findings are in keeping with prior studies reporting limited efficacy of various medications for reducing behavioral problems in demented patients.

Authors+Show Affiliations

Mt. Hope Professional Building, Rochester, NY 14620, USA. Roger_Kurlan@urmc.rochester.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

17452579

Citation

Kurlan, Roger, et al. "Quetiapine for Agitation or Psychosis in Patients With Dementia and Parkinsonism." Neurology, vol. 68, no. 17, 2007, pp. 1356-63.
Kurlan R, Cummings J, Raman R, et al. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007;68(17):1356-63.
Kurlan, R., Cummings, J., Raman, R., & Thal, L. (2007). Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology, 68(17), 1356-63.
Kurlan R, et al. Quetiapine for Agitation or Psychosis in Patients With Dementia and Parkinsonism. Neurology. 2007 Apr 24;68(17):1356-63. PubMed PMID: 17452579.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. AU - Kurlan,Roger, AU - Cummings,Jeffrey, AU - Raman,Rema, AU - Thal,Leon, AU - ,, PY - 2007/4/25/pubmed PY - 2007/5/11/medline PY - 2007/4/25/entrez SP - 1356 EP - 63 JF - Neurology JO - Neurology VL - 68 IS - 17 N2 - OBJECTIVE: To assess the efficacy and tolerability of quetiapine for agitation or psychosis in patients with dementia and parkinsonism. METHODS: Multicenter randomized, double-blind, placebo-controlled parallel groups clinical trial involving 40 patients with dementia with Lewy bodies (n = 23), Parkinson disease (PD) with dementia (n = 9), or Alzheimer disease with parkinsonian features (n = 8). The main outcome measure for efficacy was change in the Brief Psychiatric Rating Scale (BPRS) from baseline to 10 weeks of therapy. For tolerability it was change in the Unified PD Rating Scale (UPDRS) motor section over the same time period. The trial was confounded by the need for a design change and incomplete recruitment. RESULTS: No significant differences in the primary or secondary outcome measures of efficacy were observed. An unexpectedly large placebo effect, inadequate dosage (mean 120 mg/day), and inadequate power may have contributed to lack of demonstrable benefit. Quetiapine was generally well-tolerated and did not worsen parkinsonism, but was associated with a trend toward a decline on a measure of daily functioning. CONCLUSIONS: Quetiapine was well-tolerated and did not worsen parkinsonism. Although conclusions about efficacy may be limited, the drug in the dosages used did not show demonstrable benefit for treating agitation or psychosis in patients with dementia and parkinsonism. These findings are in keeping with prior studies reporting limited efficacy of various medications for reducing behavioral problems in demented patients. SN - 1526-632X UR - https://www.unboundmedicine.com/medline/citation/17452579/Quetiapine_for_agitation_or_psychosis_in_patients_with_dementia_and_parkinsonism_ L2 - http://www.neurology.org/cgi/pmidlookup?view=long&pmid=17452579 DB - PRIME DP - Unbound Medicine ER -